论文部分内容阅读
将５１例晚期恶性肿瘤患者（男性２３例，女性２８例）分成两组，其中一组（３１例）以ＣＤ３ＭｃＡｂ（ＣＤ３单克隆抗体）和小剂量ＩＬ－２（５００ｕ／ｍｌ）共同诱导的ＣＤ３ＡＫ细胞治疗，另一组（２０例）输注大剂量ＩＬ－２（１０００ｕ／ｍｌ）诱导的常规ＬＡＫ细胞治疗，以探讨降低ＩＬ－２用量、提高杀伤细胞细胞毒活性的可能性。结果显示ＣＤ３ＡＫ组患者生活质量改善、症状缓解均优于ＬＡＫ组。ＣＤ３ＡＫ组ＰＲ＋ＭＲ率较ＬＡＫ组高２９．０％，Ｓ＋Ｐ率和死亡率分别较ＬＡＫ组低１２．４％和９．６％。同时比较了ＣＤ３ＡＫ细胞与ＬＡＫ细胞的体外增殖和细胞毒活性，结果表明ＣＤ３ＡＫ细胞增殖率高于ＬＡＫ细胞（Ｐ＜０．０１），靶细胞抑制率二者在０．０５水平无显著差异。提示ＣＤ３ＭｃＡｂ在刺激杀伤细胞活性，尤其在提高其增殖能力方面，具有显著的作用，ＣＤ３ＡＫ／ＩＬ－２能更有效地治疗晚期恶性肿瘤。
Fifty-one patients with advanced malignancies (23 males and 28 females) were divided into two groups. Among them, one group (31 patients) was co-induced by CD3 McAb (CD3 monoclonal antibody) and low-dose IL-2 (500 u/ml). For cell therapy, another group (20 patients) was treated with high-dose IL-2 (1000u/ml)-infused conventional LAK cells to investigate the possibility of reducing the amount of IL-2 and increasing the cytotoxic activity of the killer cells. The results showed that the improvement in quality of life and symptom relief in the CD3AK group were superior to those in the LAK group. The rate of PR+MR in the CD3AK group was 29.0% higher than that in the LAK group, and the S+P rate and death rate were 12.4% and 9.6% lower than those in the LAK group, respectively. At the same time, the proliferation and cytotoxicity of CD3AK cells and LAK cells were compared. The results showed that the proliferation rate of CD3AK cells was higher than that of LAK cells (P<0.01), and there was no significant difference in target cell inhibition rate at 0.05 level. It is suggested that CD3McAb has a significant effect in stimulating the activity of killer cells, especially in increasing its proliferation ability, and CD3AK/IL-2 can more effectively treat advanced malignant tumors.